Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04461015 · ClinicalTrials.gov registry record · Phase 3

The Effect of the Interaction of Glucagon and Insulin on Endogenous Glucose Production in Humans

A Phase 3 study of Healthy, sponsored by Adrian Vella.

Completed
Registry status
Phase 3
Development phase
12
Enrollment target
1
Study location

NCT04461015 is a Phase 3 study of Healthy that has completed, run by Adrian Vella. The registered enrollment target is 12 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04461015, a Phase 3 study of Healthy, has completed, sponsored by Adrian Vella.

COMPLETED
Registry status
Phase 3
Development phase
12 participants
Enrollment target
1
Study location

Study Summary

The purpose of this research is to help understand the relative importance of changes in insulin secretion (which lowers glucose) and changes in glucagon (which raises glucose) to regulate metabolism and the body's ability to make glucose.

Conditions Studied

Interventions

  • DRUG 0.4mU Insulin followed by withdrawal period followed by 0.8mU study
  • DRUG 0.8mU Insulin followed by withdrawal period followed by 0.4mU study

Study Locations (1)

Minnesota

  • Mayo Clinic in Rochester - Rochester

Trial Details

FieldValue
Enrollment Target 12 participants
Start Date 2020-10-14
Est. Completion 2022-01-06
Phase Phase 3

Sponsor

Adrian Vella

9 total trials

What the Registry Record Tells You About NCT04461015

The ClinicalTrials.gov registry entry for NCT04461015 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (98% lower). The listed sponsor is Adrian Vella, which has 9 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Healthy appearing as the primary indexed condition, and to 2 interventions - of which 0.4mU Insulin followed by withdrawal period followed by 0.8mU study is the first listed.

NCT04461015 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.

Frequently Asked Questions

What is clinical trial NCT04461015 about?

NCT04461015 is a clinical study titled "The Effect of the Interaction of Glucagon and Insulin on Endogenous Glucose Production in Humans". The purpose of this research is to help understand the relative importance of changes in insulin secretion (which lowers glucose) and changes in glucagon (which raises glucose) to regulate metabolism and the body's ability to make glucose.

What is the current status of trial NCT04461015?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 12 participants. The study started on 2020-10-14. Estimated completion is 2022-01-06.

What conditions does trial NCT04461015 study?

This clinical trial studies the following conditions: Healthy.

What interventions are being tested in trial NCT04461015?

The interventions under investigation include: 0.4mU Insulin followed by withdrawal period followed by 0.8mU study (DRUG), 0.8mU Insulin followed by withdrawal period followed by 0.4mU study (DRUG).

Who is sponsoring clinical trial NCT04461015?

This trial is sponsored by Adrian Vella, which has 9 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04461015 being conducted?

This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Healthy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.